apl. Prof. Dr. Peter Goebell

Medizinische Fakultät Urologische Klinik

A prospective, open-label, multicenter, randomized phase II trial: Sequential therapy with BEvacizumab, RAd001 (Everolimus) and AxiTinib in metastatic renal cell carcinoma (mRCC) (BERAT study of the IAG-N) (2022) Hilser T, Gruenwald V, Bergmann L, Goebell P, Strauss A, Meiler J, Hartmann A, et al. Conference contribution Prognostic potential of baseline HRQoL in advanced and metastatic renal cell carcinoma (2022) Gruenwald V, Goebell P, Schostak M, Welslau M, Doehn C, Degenkolbe E, Ehness R, et al. Conference contribution Cell-Free DNA Sequencing Reveals Gene Variants in DNA Damage Repair Genes Associated with Prognosis of Prostate Cancer Patients (2022) Lieb V, Abdulrahman A, Weigelt K, Hauch S, Gombert M, Guzman J, Bellut L, et al. Journal article The Non-Interventional PAZOREAL Study to Assess the Effectiveness and Safety of Pazopanib in a Real-Life Setting: Reflecting a Changing mRCC Treatment Landscape (2022) Doehn C, Bögemann M, Grünwald V, Welslau M, Bedke J, Schostak M, Wolf T, et al. Journal article Treatment of patients with advanced urothelial carcinoma in routine care in Germany: initial data from the CARAT-UBC cohort (2022) Goebell P, Mueller L, Boegemann M, Rauh J, Nusch A, Andres-Pons A, Hamm N, et al. Conference contribution Drug Therapy Safety with new oral Antitumor Agents for the Therapy of Prostate and Renal Cell Carcinoma: Findings from the AMBORA Study (2022) Cuba L, Schlichtig K, Dürr P, Bellut L, Meidenbauer N, Kunath F, Goebell P, et al. Conference contribution New Oral Antitumor Drugs and Medication Safety in Uro-Oncology: Implications for Clinical Practice Based on a Subgroup Analysis of the AMBORA Trial (2022) Schlichtig K, Cuba L, Dürr P, Bellut L, Meidenbauer N, Kunath F, Goebell P, et al. Journal article LACK OF CONCORDANCE BETWEEN REAL-WORLD TREATMENT PATTERNS AND CLINICAL GUIDELINE RECOMMENDATIONS FOR METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC) PATIENTS (2022) Goebell P, Shah R, Raina R, Rege S, Chen S, Partridge J, Waldeck R Conference contribution A Prospectivly Randomized Phase-II Trial of Axitinib versus Everolimus as Second-Line Therapy in Metastatic Renal Cell Carcinoma (BERAT Study) (2022) Grünwald V, Hilser T, Meiler J, Goebell P, Ivanyi P, Strauss A, Hartmann A, et al. Journal article Analysis of the Impact of Clinical Factors on Low-Intensity Extracorporeal Shockwave Therapy for Erectile Dysfunction (2022) Oginski N, Apel H, Richterstetter M, Lieb V, Fiebig C, Goebell P, Wullich B, Sikic D Journal article